Quality assurance of radiotherapy in the ongoing EORTC 1420 "Best of" trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure.

INTRODUCTION: The current phase III EORTC 1420 Best-of trial (NCT02984410) compares the swallowing function after transoral surgery versus intensity modulated radiotherapy (RT) in patients with early-stage carcinoma of the oropharynx, supraglottis and hypopharynx. We report the analysis of the Benchmark Case (BC) procedures before patient recruitment with special attention to dysphagia/aspiration related structures (DARS). MATERIALS AND METHODS: Submitted RT volumes and plans from participating centers were analyzed and compared against the gold-standard expert delineations and dose distributions. Descriptive analysis of protocol deviations was conducted. Mean Sorensen-Dice similarity index (mDSI) and Hausdorff distance (mHD) were applied to evaluate the inter-observer variability (IOV). RESULTS: 65% (23/35) of the institutions needed more than one submission to achieve Quality assurance (RTQA) clearance. OAR volume delineations were the cause for rejection in 53% (40/76) of cases. IOV could be improved in 5 out of 12 OARs by more than 10 mm after resubmission (mHD). Despite this, final IOV for critical OARs in delineation remained significant among DARS by choosing an aleatory threshold of 0.7 (mDSI) and 15 mm (mHD). CONCLUSIONS: This is to our knowledge the largest BC analysis among Head and neck RTQA programs performed in the framework of a prospective trial. Benchmarking identified non-common OARs and target delineations errors as the main source of deviations and IOV could be reduced in a significant number of cases after this process. Due to the substantial resources involved with benchmarking, future benchmark analyses should assess fully the impact on patients' clinical outcome.

Monte carlo evaluation of the AAA treatment planning algorithm in a heterogeneous multilayer phantom and IMRT clinical treatments for an Elekta SL25 linear accelerator.

The Anisotropic Analytical Algorithm (AAA) is a new pencil beam convolution/superposition algorithm proposed by Varian for photon dose calculations. The configuration of AAA depends on linear accelerator design and specifications. The purpose of this study was to investigate the accuracy of AAA for an Elekta SL25 linear accelerator for small fields and intensity modulated radiation therapy (IMRT) treatments in inhomogeneous media. The accuracy of AAA was evaluated in two studies. First, AAA was compared both with Monte Carlo (MC) and the measurements in an inhomogeneous phantom simulating lung equivalent tissues and bone ribs. The algorithm was tested under lateral electronic disequilibrium conditions, using small fields (2 x 2 cm(2)). Good agreement was generally achieved for depth dose and profiles, with deviations generally below 3% in lung inhomogeneities and below 5% at interfaces. However, the effects of attenuation and scattering close to the bone ribs were not fully taken into account by AAA, and small inhomogeneities may lead to planning errors. Second, AAA and MC were compared for IMRT plans in clinical conditions, i.e., dose calculations in a computed tomography scan of a patient. One ethmoid tumor, one orophaxynx and two lung tumors are presented in this paper. Small differences were found between the dose volume histograms. For instance, a 1.7% difference for the mean planning target volume dose was obtained for the ethmoid case. Since better agreement was achieved for the same plans but in homogeneous conditions, these differences must be attributed to the handling of inhomogeneities by AAA. Therefore, inherent assumptions of the algorithm, principally the assumption of independent depth and lateral directions in the scaling of the kernels, were slightly influencing AAA's validity in inhomogeneities. However, AAA showed a good accuracy overall and a great ability to handle small fields in inhomogeneous media compared to other pencil beam convolution algorithms.

[The TomoTherapy Hi.Art System for sophisticated IMRT and IGRT with helical delivery: Recent developments and clinical applications]. / Le système de tomothérapie hélicoïdale pour la radiothérapie modulée en intensité et guidée par l'image: développements récents et applications cliniques.

The advent of 3D conformal radiotherapy and intensity modulated radiation therapy (IMRT) make possible the dose optimization to complex target volumes close to sane organs at risk. IMRT's introduction of numerous small radiation fields inherently increases delivery inaccuracies. As a consequence, the use of IMRT without precise localization of the tumor and sensitive structures, at both the planning and delivery stages, and the absence of continuous verification represent the most significant challenges to the implementation of IMRT in routine clinical use. Intensity modulated (or not) conformal radiotherapy delivery requires better precision in the definition of treatment volume, frequently if necessary. Helical tomotherapy has been designed to use CT imaging technology to plan, deliver, and verify that the delivery has been carried out as planned. The image-guided and intensity modulations processes of helical tomotherapy that enable this goal are described.

[Quality assurance program for intensity-modulated radiotherapy (IMRT) treatments of head and neck carcinomas]. / Programme commun d'assurance de qualité de la radiothérapie conformationnelle avec modulation d'intensité (RCMI) des cancers de la tête et du cou.

A new technique such as intensity-modulated radiotherapy needs a quality assurance program. A French cooperative group joined to define a common program for the use of this technique in the case of head and neck carcinomas. Specific controls are necessary and even mandatory, for example: leaves position, speed of the leaves and the linearity of the dose with the monitor unit number. Measurements in homogeneous phantoms will validate calculated treatment plans. Absolute and relative measurements need ionisation chambers and films. Measurements for each beam, gantry at 0 degrees, are basic measurements. If those are impossible due to the treatment planning software, they can be performed with the treatment angles, films of course positioned perpendicularly to the beam axis. A consensus must be established between members to reduce the frequency and the number of measurements. Nevertheless, it currently seems mandatory to maintain measurements for each beam. Moreover, incidents that happen during this kind of treatment have to be recorded and new verifications will have to be realised then. This program is a unique possibility to match the application of a new technique whatever the type of equipment.

[Recommendations for a head and neck IMRT quality assurance protocol]. / Recommandations pour un protocole d'assurance de qualité de la radiothérapie conformationnelle avec modulation d'intensité des cancers de la tête et du cou.

Head and neck tumors represent very interesting targets for IMRT techniques because of the complex shape of the structures and the organs at risk close by. The use of this kind of techniques requires a quality assurance protocol. The physicists of the GORTEC group shared their experience to define some recommendations in order to draw up a QA protocol. The dosimetric verification of the treatment plans (in terms of absolute and relative dose), the control of the reproducibility of the patient positioning and the use of a record and verify system to control the different parameters form the main parts of these recommendations. Each chapter comprises a description of the different methods, recommendations concerning the equipment, the adopted tolerances, the frequency of controls. At the end of each chapter, a table summarizes the main actions to carry out. These recommendations will allow to harmonize our practices whatever the softwares and the accelerator that are being used. They will simplify the task of the teams that wish to implement IMRT for head and neck tumors.

Development of clinical trial protocols involving advanced radiation therapy techniques: the European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach.

The European Organisation for Research and Treatment of Cancer (EORTC) Master Protocol for phase III radiation therapy (RT) studies was published in 1995 to define in a consistent sequence the parameters which must be addressed when designing a phase III trial 'from the rationale to the references'. This was originally implemented to assist study investigators and writing committees, and to increase homogeneity within Radiation Oncology Group (ROG) study protocols. However, RT planning, delivery, treatment verification and quality assurance (QA) have evolved significantly over the last 15 years and clinical trial protocols must reflect these developments. The goal of this update is to describe the incorporation of these developments into the EORTC-ROG protocol template. Implementation of QA procedures for advanced RT trials is also briefly described as these essential elements must also be clearly articulated. This guide may assist both investigators participating in current ROG trials and others involved in writing an advanced RT trial protocol.

[Quality assurance in radiotherapy]. / Assurance de la qualité en radiothérapie.

Quality assurance in radiotherapy affects the radiotherapy department organization, management, patient follow-up, distribution of responsibilities, training and equipment management. The development of innovative techniques for radiotherapy and associated radiotherapy equipment requires an adaptation of the concepts of quality assurance and quality control as practiced last 30 years. A new paradigm and new methods adapted from industry, including patient safety and quality care in a more holistic approach to quality assurance and quality control.